[go: up one dir, main page]

DK1622929T3 - Apo-2L (TRAIL) receptorbindingspeptider og anvendelser deraf - Google Patents

Apo-2L (TRAIL) receptorbindingspeptider og anvendelser deraf

Info

Publication number
DK1622929T3
DK1622929T3 DK04760861T DK04760861T DK1622929T3 DK 1622929 T3 DK1622929 T3 DK 1622929T3 DK 04760861 T DK04760861 T DK 04760861T DK 04760861 T DK04760861 T DK 04760861T DK 1622929 T3 DK1622929 T3 DK 1622929T3
Authority
DK
Denmark
Prior art keywords
apo
trail
receptor binding
binding peptides
peptides
Prior art date
Application number
DK04760861T
Other languages
English (en)
Inventor
Bing Li
Sachdev S Sidhu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1622929T3 publication Critical patent/DK1622929T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK04760861T 2003-05-09 2004-04-29 Apo-2L (TRAIL) receptorbindingspeptider og anvendelser deraf DK1622929T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46943603P 2003-05-09 2003-05-09
PCT/US2004/013576 WO2004101608A2 (en) 2003-05-09 2004-04-29 Apo2l (trail) receptor binding peptides and uses thereof

Publications (1)

Publication Number Publication Date
DK1622929T3 true DK1622929T3 (da) 2007-02-19

Family

ID=33452286

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06013626T DK1754713T3 (da) 2003-05-09 2004-04-29 Peptider, der binder sig til Apo2L (Trail)-receptorer samt anvendelser deraf
DK04760861T DK1622929T3 (da) 2003-05-09 2004-04-29 Apo-2L (TRAIL) receptorbindingspeptider og anvendelser deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK06013626T DK1754713T3 (da) 2003-05-09 2004-04-29 Peptider, der binder sig til Apo2L (Trail)-receptorer samt anvendelser deraf

Country Status (12)

Country Link
US (1) US20070066800A1 (da)
EP (2) EP1622929B1 (da)
JP (1) JP2007530008A (da)
AT (2) ATE342274T1 (da)
AU (1) AU2004238794A1 (da)
CA (1) CA2524456A1 (da)
DE (2) DE602004002773T2 (da)
DK (2) DK1754713T3 (da)
ES (2) ES2322182T3 (da)
IL (1) IL171733A (da)
PL (2) PL1622929T3 (da)
WO (1) WO2004101608A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1756162A1 (en) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US20090131317A1 (en) * 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
WO2010111842A1 (zh) * 2009-04-03 2010-10-07 中国医学科学院基础医学研究所 抗人死亡受体dr5单克隆抗体ad5-10所识别的抗原决定簇、其衍生物及其用途
CA2777162A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
FR3031112B1 (fr) * 2014-12-24 2018-05-25 Eyevensys Construction d'adn pour le traitement de pathologies oculaires
CN105061604B (zh) * 2015-08-19 2018-03-16 河南大学 sDR5‑Fc融合蛋白突变体及其应用
CA3008392C (en) 2015-12-17 2021-11-09 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EP3439687A1 (en) 2016-04-07 2019-02-13 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
CN116585484B (zh) * 2022-12-13 2023-12-12 广州医科大学 多肽偶联小分子化合物及其抗病毒应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method

Also Published As

Publication number Publication date
IL171733A (en) 2010-11-30
US20070066800A1 (en) 2007-03-22
AU2004238794A1 (en) 2004-11-25
EP1622929B1 (en) 2006-10-11
ES2322182T3 (es) 2009-06-17
PL1622929T3 (pl) 2007-03-30
WO2004101608A3 (en) 2004-12-29
WO2004101608A2 (en) 2004-11-25
ATE423786T1 (de) 2009-03-15
JP2007530008A (ja) 2007-11-01
DE602004019701D1 (de) 2009-04-09
DE602004002773D1 (de) 2006-11-23
CA2524456A1 (en) 2004-11-25
EP1622929A2 (en) 2006-02-08
PL1754713T3 (pl) 2009-07-31
EP1754713A1 (en) 2007-02-21
EP1754713B1 (en) 2009-02-25
ES2274480T3 (es) 2007-05-16
DE602004002773T2 (de) 2007-08-16
DK1754713T3 (da) 2009-06-08
ATE342274T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
ATE446771T1 (de) Taci-immunoglobulin-fusionsproteine
DK1536778T3 (da) Proteiner, der binder til cross-beta-strukturholdigt amyloid og fremgangsmåder til modulation af cross-beta-strukturen, dens dannelse og dens associerede toksicitet
DE60325892D1 (de) Stellungs- und verwendungsverfahren
WO2003104414A3 (en) Artificial transcription factors
NO20055306D0 (no) GITR ligand og GITR ligand relaterte molekyler og antistoffer og anvendelse derav
DK1450847T3 (da) Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
DK1404873T3 (da) Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
MX2009012282A (es) Estructuras cristalinas de fragmentos de neuropilina y complejos de neuropilina-anticuerpos.
DK1622929T3 (da) Apo-2L (TRAIL) receptorbindingspeptider og anvendelser deraf
ATE430526T1 (de) Einrichtung zur dynamischen stabilisierung von wirbeln
ZA200800862B (en) Cross-β structure binding compounds
WO2004013290A3 (en) Compositions and methods for molecular biology
DE602004032465D1 (de) Referenzstandard zur charakterisierung von rosuvastatin
DK1465927T3 (da) BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
DK1768691T3 (da) Aequorinholdige præparater og fremgangsmåder til anvendelse af samme
DE602004030438D1 (de) Neuartiger, zur spaltung der urethanbindung fähiger bacterie
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
DE10342518A1 (de) Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
FI20040813L (fi) Hydrofobisia molekyylejä stabiloivat proteiinit